Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs).
about
Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials.Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results data.Sperm associated antigen 9 (SPAG9) expression and humoral response in benign and malignant salivary gland tumors.Clinicopathological analysis of salivary gland carcinomas and literature review.Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications.Human Epidermal Growth Factor Receptor 2 (HER2/neu) in Salivary Gland Carcinomas: A Review of Literature.High frequency of loss of PTEN expression in human solid salivary adenoid cystic carcinoma and its implication for targeted therapy.Parotid carcinoma: Current diagnostic workup and treatment.Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers InitiativeComprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations.Breast metastasis of salivary duct carcinoma in a patient: a case report.Prognostic value of expression of molecular markers in adenoid cystic cancer of the salivary glands compared with lymph node metastasis: a retrospective studyTrastuzumab for the treatment of salivary duct carcinoma.Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients.Detailed genome-wide SNP analysis of major salivary carcinomas localizes subtype-specific chromosome sites and oncogenes of potential clinical significance.Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial.Androgen Receptor Signaling in Salivary Gland Cancer.Expression of beclin 1 in primary salivary adenoid cystic carcinoma and its relation to Bcl-2 and p53 and prognosis.Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review.Salivary duct carcinoma: what is already known, and can we improve survival?Management of salivary gland tumors.Salivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature.Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature.Molecular Pathology and Biomarkers.Novel therapeutic strategies for malignant salivary gland tumors: lessons learned from breast cancer.Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.Phosphorylated epidermal growth factor receptor expression and KRAS mutation status in salivary gland carcinomas.Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification.Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma.Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy.Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.Salivary duct carcinoma: Treatment, outcomes, and patterns of failure.Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours.Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.Sex Hormone Receptors in Benign and Malignant Salivary Gland Tumors: Prognostic and Predictive Role.A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma.Developing Androgen Receptor Targeting for Salivary Gland Cancers.Cytogenetic and immunohistochemical biomarker profiling of therapy-relevant factors in salivary gland carcinomas.A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.Combined salivary duct carcinoma and squamous cell carcinoma suspected of carcinoma ex pleomorphic adenoma.
P2860
Q30301145-526498EC-6F75-4818-A1C7-BDBBBD4C82DFQ34147330-A7F81C8D-7A28-4F5D-BF97-C9B7C203D142Q34475061-3CABD690-6202-43BF-9737-A9D68A8DBC94Q34607333-0A4084E8-3EF7-4BF3-B726-6333A44EF671Q34714945-3FDFAF80-80C2-44E8-8D0B-336316423C37Q35230643-AA8FEF74-5005-4312-B46E-4255DA0B882CQ35793835-D9FC63BA-CC66-4528-B852-9BA367B44A6AQ36170033-F0050B72-AEDF-4FB9-BA4D-15079780F61DQ36265620-87A8D14B-E3B7-49AF-8A35-0AD35B672036Q36317852-6FFD92FC-1D4F-41CD-A699-B051B040706AQ36493317-32F28D6B-8A89-4137-94C4-31D93D48B765Q36565198-DC893ABF-7283-4534-AAE4-DB594CEA0FCBQ36714388-92BA1639-B6FA-4D91-83A6-53703B329912Q36874710-7DE8A987-A135-4681-BFAD-FB2F4C8B35CDQ36888316-ECCB8336-7A8E-49B4-A83C-F37AFDDDD4C2Q37185867-DDDCAB5E-AE77-454E-8446-AF7094EB80E6Q37676074-9D1AAD73-934E-4FB5-BBFD-A87C4D834B5EQ37696799-A00F2CCA-6A56-45FA-925C-A95624CDE95AQ37774965-E9FFA00F-FB16-4F99-89D7-2E2123D229D5Q38001863-5A65D889-6762-4CAC-81D1-E091395CEACDQ38055494-844E86C0-8074-49DF-AD10-C788E5E75BFDQ38114366-951C8855-303D-459C-AAC2-0866DF2686E1Q38119240-93E7EDF4-9B6D-4A13-B405-1F72AD4CFB31Q38811776-441F5FAC-2937-4A96-BF83-1BB8584BB4E8Q39491094-2C3ECF12-7D74-4046-81B8-876FD2A49034Q40452694-53FAFC33-D5E4-492E-90CA-BA6C13C8A18BQ40657619-211D0D80-8610-4A52-B431-9487DF1FA0C6Q41708696-F9CC44D4-04A0-4A77-950C-3FA7CF7A3DA9Q42936492-0B9A1BF3-DFC1-4B61-82A3-DD393F2810DCQ44458754-2EFFE6A1-6358-4896-9EB0-97EC8DA6273BQ47259493-C679C920-3AB0-4C90-9248-3F3A83F14E4EQ47569604-8652B035-86B2-4A39-9D31-6E14A9AD2644Q47811507-0090C3A3-8D9C-4100-94E6-A695053086CBQ48123633-9674E946-94C6-4484-A920-B0AB74B9C74DQ49550534-877C7FCB-BE29-443B-A9AC-A596C933F04DQ50049535-BFDA1A2D-A8C5-49DE-929F-06CBCEE4B7C0Q50132910-8048E8B5-F20D-47ED-8BD5-44416D82730AQ50675747-8524EF1B-BF6D-43F9-9E8D-749044467704Q52680181-DD957246-FB8D-4091-A188-EB2963C215C0Q52859201-D1713B31-9264-445F-94E9-B6CC31E0544F
P2860
Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs).
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs).
@en
Treatment relevant target immunophenotyping of 139 salivary gland carcinomas
@nl
type
label
Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs).
@en
Treatment relevant target immunophenotyping of 139 salivary gland carcinomas
@nl
prefLabel
Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs).
@en
Treatment relevant target immunophenotyping of 139 salivary gland carcinomas
@nl
P2093
P50
P1433
P1476
Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs).
@en
P2093
Barbara Cortelazzi
Cecilia Liberatoscioli
Gaetana Rinaldi
Marco Losa
Marta Orsenigo
Micol Mela
Paola Casieri
Rosa G Calderone
P304
P356
10.1016/J.ORALONCOLOGY.2009.05.635
P407
P50
P577
2009-07-01T00:00:00Z